The devastating loss of their daughter, Megan, to Meningitis B has transformed Helen and Lee Draper into passionate advocates, urging parents to understand the full spectrum of meningitis vaccinations and imploring the government to re-evaluate current policies to prevent similar tragedies.
The death of university student Megan Draper in October 2025 from Meningitis B has brought to the forefront critical questions about vaccine awareness and public health policy in the United Kingdom. Her parents, Helen and Lee Draper, discovered with profound anguish that their daughter, a student at Bournemouth University, had not been vaccinated against the specific strain of bacterial meningitis that claimed her life. This revelation has propelled them into a determined campaign, highlighting a perceived gap in public understanding regarding the comprehensive protection offered by available meningitis vaccines and advocating for a governmental reconsideration of current vaccination strategies. Their appeal underscores the vital importance of informed decision-making for parents and robust public health initiatives to safeguard young people.
Megan Draper’s untimely death sent shockwaves through her family and the Bournemouth University community. A vibrant young woman embarking on her university journey, Megan’s life was tragically cut short by a disease known for its rapid progression and severe outcomes. Meningitis, an inflammation of the membranes surrounding the brain and spinal cord, can be caused by various bacteria and viruses, with bacterial forms being particularly dangerous. The specific strain that afflicted Megan, Meningitis B, is a leading cause of bacterial meningitis in the UK and Ireland, especially among infants and young children, but also poses a significant threat to adolescents and young adults, particularly those in close living environments like university halls.
The Drapers’ subsequent discovery that Megan was not protected against Meningitis B revealed a critical lapse in what they believed was comprehensive vaccination coverage. This experience has illuminated a broader issue: the complexity of meningitis vaccination schedules and the potential for misunderstanding among the general public regarding the different strains of the disease and the specific protection each vaccine offers. Lee Draper, Megan’s father, has articulated this concern powerfully, emphasizing the paramount importance for parents to be fully aware that the meningitis vaccinations their children receive must protect against all prevalent strains, not just a select few. His statement points to a common misconception that a "meningitis vaccine" provides universal immunity, when in fact, multiple vaccines are required to cover the most common and dangerous serogroups.
Meningitis B, caused by the bacterium Neisseria meningitidis serogroup B, presents unique challenges for vaccine development and public health policy. Unlike some other serogroups, MenB has a highly variable outer coat, making it difficult to create a single, broadly effective vaccine. The MenB vaccine, Bexsero, was introduced into the UK’s routine childhood immunization programme in September 2015 for infants. This landmark decision made the UK the first country in the world to offer a national MenB vaccination programme. Infants receive doses at two and four months, followed by a booster at 12 months. However, the introduction date means that many older children, adolescents, and young adults, like Megan, would have been too old to receive the vaccine as part of the routine childhood schedule. While a catch-up programme for older age groups was not implemented due to cost-effectiveness considerations and logistical complexities, the vaccine remains available privately.
The vulnerability of university students to meningococcal disease, including Meningitis B, is a well-documented public health concern. Moving into communal living spaces, often for the first time, exposes young adults to a greater risk of transmitting infectious diseases. Close contact, shared facilities, and new social networks facilitate the spread of bacteria like Neisseria meningitidis, which can reside harmlessly in the throats and noses of about one in ten people but can cause severe illness in others. Universities, therefore, are recognized as environments where vigilance against meningitis and other infectious diseases is crucial. Public health bodies consistently advise students to be aware of symptoms and to ensure their vaccinations are up to date, specifically mentioning the MenACWY vaccine for adolescents and the MenB vaccine.
The symptoms of meningitis can be subtle initially, often mimicking less serious illnesses like the flu, which contributes to the difficulty in early diagnosis. These can include a high fever, headache, stiff neck, aversion to bright lights, drowsiness, joint pain, and a rash that doesn’t fade under pressure (the ‘tumbler test’). The disease can progress extremely rapidly, sometimes within hours, leading to severe complications such as septicaemia (blood poisoning), brain damage, hearing loss, and limb amputation, or even death. The speed of onset and potential for devastating outcomes underscore why preventative measures, particularly vaccination, are so critical.
Helen Draper, Megan’s mother, has articulated a poignant and direct plea, stating she "absolutely implores the government to reconsider this." Her call is likely multifaceted, extending beyond just the availability of the MenB vaccine. It implicitly urges a comprehensive review of the current vaccination policy for adolescents and young adults, greater public health messaging to highlight the distinction between different meningitis vaccines, and potentially, an expansion of the funded vaccination programme to include older age groups at higher risk, such as university entrants. The "this" she refers to could encompass the scope of the national immunization programme, the intensity of public awareness campaigns, or the accessibility of vital information and vaccines.
Public health policy decisions are complex, balancing scientific evidence, cost-effectiveness, ethical considerations, and societal impact. When new vaccines become available, independent expert committees, such as the Joint Committee on Vaccination and Immunisation (JCVI) in the UK, evaluate their suitability for inclusion in national programmes. Factors considered include disease burden, vaccine efficacy and safety, potential for herd immunity, and the financial implications for the National Health Service. While the MenB vaccine was introduced for infants, a universal programme for older age groups has not been adopted, often due to analyses suggesting a lower overall cost-effectiveness compared to the infant programme, given the lower incidence rate in older children relative to infants. However, the Drapers’ advocacy brings the human cost of these decisions into sharp focus, compelling a re-evaluation of the societal value beyond purely economic metrics.
The Drapers’ campaign resonates with many parents who are increasingly seeking to understand the nuances of childhood and adolescent vaccination. They advocate for a level of transparency and detail in public health communications that empowers parents to make truly informed decisions. This includes clarifying that the MenACWY vaccine, typically offered to teenagers to protect against meningococcal serogroups A, C, W, and Y, does not provide protection against serogroup B. This distinction is often lost amidst the general advice to get "the meningitis vaccine."
Beyond governmental policy, universities and educational institutions also have a vital role to play in promoting student health. Many universities already provide information on meningitis vaccination and symptoms as part of their induction processes, often in collaboration with local NHS services. However, the Drapers’ experience suggests there may be a need for more direct, targeted, and persistent messaging, especially concerning the MenB vaccine for those who fall outside the routine infant vaccination schedule. This could involve recommending private vaccination for students not covered by the NHS programme or facilitating access to information on where to obtain it.
The urgent call from Helen and Lee Draper following Megan’s tragic death serves as a powerful reminder of the devastating impact of preventable diseases and the critical role of robust public health strategies. Their advocacy underscores the need for continuous review of vaccination policies, enhanced public awareness campaigns, and clear, unambiguous communication about the specific protections offered by different vaccines. As the Drapers continue their fight, their message is clear: understanding the full scope of meningitis vaccinations is not merely a recommendation but a vital safeguard, potentially saving lives and preventing other families from enduring the profound grief they now carry. Their efforts aim to ensure that Megan’s legacy is one of increased awareness and proactive measures, ensuring no other family suffers a similar, preventable loss.